BioIVT Launches Human AB Serum Product Line to Facilitate Cell and Gene Therapy Development

PRESS RELEASE FROM BIOIVT
August 30, 2021
Press Contacts
Lisa Osborne
Rana Healthcare Solutions LLC
(206) 992-5245
WESTBURY, N.Y. —

These new products create biologically relevant conditions to shorten cell expansion times.  

 

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the launch of its human AB serum product line to supplement cell culture media and facilitate cell and gene therapy development.  

 

Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human AB serum produces biologically relevant conditions that allow many human cell lines to grow at a faster rate. In addition, a smaller percentage of this serum is required than mixed blood type human serum.  

 

“BioIVT collects blood donations from more than 17,000 donors annually at donor centers located throughout the US and in the UK, so we have a strong, vertically integrated supply chain to support this new product portfolio,” said BioIVT Chief Commercial Officer Alan Findlater. “Furthermore, our recent acquisition of Valley Biomedical Products & Services, Inc. is allowing us to generate larger lots with shorter production times. Valley Biomedical has an excellent track record and has provided the pharmaceutical, biotechnology and academic R&D markets with high quality blood products and cell culture sera for the past 25 years.”  

 

BioIVT is offering both plasma-derived and off-the-clot serum collected from healthy, male AB blood type donors. All products are sterile, filtered, and ready for cell culture.  

 

Customers also have the option to heat-inactivate their serum, to deactivate complement and improve lot-to-lot reliability.  

 

All donor units are tested at the collection facility for viral markers in accordance with current US Food and Drug Administration regulations to ensure they are non-reactive prior to use. Additional testing is also available depending on customers’ needs. The final serum product also undergoes extensive quality control testing before release for distribution.  

###
About BioIVT
About BioIVT BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.